title: [Interest of the radiotherapy-hormonotherapy association in the treatment of the high-risk prostate cancer].
abstract: Treatment of high-risk prostate cancer - localized or locally advanced - is based on the combination of external irradiation and hormonal treatment by LHRH analogue (aLHRH) according to the results of phases III randomized trials RTOG and/or EORTC trials. These trials show a significant improvement of overall or specific survival. Localized prostate cancer require 6-month complete androgen blockade, while locally advanced prostate cancer need a long-term hormonal treatment for a duration ranging from 2,5 to 3 years. Some trials, which have a long follow-up show that the risk of cardiovascular death is not significantly increased by hormonal treatment.
authors.affiliation: Clinique universitaire de cancérologie-radiothérapie, centre hospitalier universitaire, Grenoble, France. MBolla@chu-grenoble.fr
authors.forename: M
authors.initials: M
authors.lastname: Bolla
authors.forename: P
authors.initials: P
authors.lastname: Fourneret
authors.forename: J-L
authors.initials: JL
authors.lastname: Descotes
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D003131:Combined Modality Therapy / Q000379:methods; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D016032:Randomized Controlled Trials as Topic
chemical_list: D000726:Androgen Antagonists; D017430:Prostate-Specific Antigen